2024年8月28日 · MK-6070（又名 HPN328）最初由 Harpoon Therapeutics 开发，它是 DLL3 × CD3 × albumin 三抗，为一种靶向 DLL3 的 T 细胞接合剂 。 MK-6070 包含 3 个结合域，旨在重定向 T 细胞以杀死表达 DLL3 的癌细胞：抗 DLL3 用于靶向接合，抗 CD3 用于 T 细胞接合，抗白蛋白用于延长半衰期。 2024 年 1 月，默沙东斥资 6.8 亿美元收购了 Harpoon 公司，从而获得了包括 MK-6070 在内的一系列在研疗法。 今年 8 月 7 日，第一三共又和默沙东宣布扩展双方现有的全 …

2024年8月6日 · MK-6070 is a T-cell engager targeting DLL3, an inhibitory canonical Notch ligand that is expressed at high levels in small cell lung cancer (SCLC) and neuroendocrine tumors, currently being evaluated in a Phase 1/2 clinical trial (NCT04471727).

2024年8月6日 · MK-6070 is a T-cell engager targeting DLL3, an inhibitory canonical Notch ligand that is expressed at high levels in small cell lung cancer (SCLC) and neuroendocrine tumors, currently being evaluated in a Phase 1/2 clinical trial (NCT04471727).

-6070 (HPN328) mechan. CRS and ICANS were graded according to ASTCT 2019 criteria. ICANS, immune efector cell-associated neurotoxicity syndrome. a69% in partic. ise noted. Percentages may not sum to 100% due to rounding. PD-(L)1, programmed cell death protein 1 or programmed cell death ligand 1. . and the maximum tolerated target dose has not be.

2024年8月12日 · MK-6070是一款靶向DLL3的T细胞接合器，DLL3是一种抑制性典型Notch配体，在小细胞肺癌（SCLC）和神经内分泌肿瘤中表达水平较高， 目前正在1/2期临床试验中进行评估。 这两家公司正计划评估MK-6070与ifinatamab deruxtecan（I-DXd）联合治疗某些SCLC患者的效果，以及其他潜在的联合治疗效果。 这项合作开始于2023年10月，第一三共和默沙东就第一三共的三款ADC候选药物：patritumab deruxtecan（HER3-DXd）、ifinatamab deruxtecan（I …

Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include Merck’s MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager.

2024年8月5日 · MK-6070 is a T-cell engager targeting DLL3, an inhibitory canonical Notch ligand that is expressed at high levels in small cell lung cancer (SCLC) and neuroendocrine tumors, currently being evaluated in a phase 1/2 clinical trial.

2024年8月7日 · MK-6070是一种靶向DLL3的T细胞衔接剂，是默克去年6.5亿美元收购Harpoon时所得。 HSA是为了增加抗体的半衰期，靶向DLL3的抗体为纳米抗体，而结合CD3的抗体为scFv形式。 目前正在进行1/2期临床试验，测试其作为单一疗法以及与罗氏的PD-L1抑制剂Tecentriq联合使用的疗效。 疗效方面，肿瘤患者接受4.1- 41.4个月治疗后，其中一位患者达到了PR；7位患者在治疗的过程中有观察到肿瘤体积缩小，其中5位患者为SCLC；肿瘤体积缩小大于的30%的3位 …

2024年8月6日 · Daiichi Sankyo and Merck announced plans to expand their global collaboration to include MK-6070, a delta-like ligand 3 (DLL3) targeting T-cell engager, in their existing co-development and co-commercialization agreement for three investigational deruxtecan (DXd) antibody-drug conjugates.

Introduction • Delta-like ligand 3 (DLL3) is an inhibitory ligand of Notch signaling that is highly expressed on the cell surface of small cell lung cancer (SCLC) and other high-grade or poorly differentiated neuroendocrine tumors or carcinomas (NET/NEC)1 • MK-6070, also known as HPN328, is a DLL3-targeting T-cell engager developed using the TriTAC®